Table 1.
Baseline characteristics of patients with early-onset and average-onset esophagogastric cancer
| Overall | Average onset | Early onset | P | |
|---|---|---|---|---|
| (N = 1123) | (n = 904) | (n = 219) | ||
| Age at diagnosis, y | ||||
| Mean (SD) | 61.6 (13.5) | 66.8 (8.7) | 40.4 (7.5) | <.0001 |
| Median (min, max) | 64.0 (18.3, 94.0) | 67.0 (50.0, 94.0) | 42.8 (18.3, 50.0) | |
| Sex, No. (%) | ||||
| Female | 338 (30.1) | 253 (28.0) | 85 (38.8) | .002325 |
| Male | 785(69.9) | 651 (72.0) | 134 (61.2) | |
| Race, No. (%) | ||||
| Asian | 113 (10.1) | 78 (8.6) | 35 (16.0) | .0014 |
| Black or African American | 50 (4.4) | 40 (4.4) | 10 (4.6) | .85 |
| White | 884 (78.7) | 741 (82.0) | 143 (65.3) | <.0001 |
| Other | 38 (3.4) | 20 (2.2) | 18 (8.2) | <.0001 |
| Unknown | 38 (3.4) | 25 (2.8) | 13 (5.9) | |
| Ethnicity, No. (%) | ||||
| Hispanic or Latino | 91 (8.1) | 55 (6.1) | 36 (16.4) | <.0001 |
| Not Hispanic or Latino | 985 (87.7) | 807 (89.3) | 178 (81.3) | |
| Unknown | 47 (4.2) | 42 (4.6) | 5 (2.3) | |
| Body mass index, kg/m2 | ||||
| Mean (SD) | 27.6 (5.63) | 27.8 (5.36) | 26.9 (6.62) | .0099 |
| Median (Min, Max) | 26.9 (11.6, 56.8) | 27.1 (15.2, 56.4) | 26.2 (11.6, 56.8) | |
| Missing, No. (%) | 33 (2.9) | 24 (2.7) | 9 (4.1) | |
| Smoking status, No. (%) | ||||
| Yes | 401 (35.7) | 352 (38.9) | 49 (22.4) | <.0001 |
| No | 334 (29.7) | 246 (27.2) | 88 (40.2) | |
| Missing | 388 (34.6) | 306 (33.9) | 82 (37.4) | |
| Alcohol use, No. (%) | ||||
| Yes | 340 (30.3) | 271 (30.0) | 69 (31.5) | .69 |
| No | 191 (17.0) | 158 (17.5) | 33 (15.1) | |
| Missing | 592 (52.7) | 475 (52.5) | 117 (53.4) | |
| Histology/Lauren classification, No. (%) | ||||
| Adenocarcinoma | 874 (77.8) | 738 (81.6) | 136 (62.1) | <.0001 |
| Signet ring and/or diffuse type | 174 (15.5) | 100 (11.1) | 74 (33.8) | <.0001 |
| Squamous cell carcinoma | 26 (2.3) | 24 (2.7) | 2 (0.9) | .21 |
| Other | 49 (4.4) | 42 (4.7) | 7 (0.9) | .46 |
| Primary site binary, No. (%) | ||||
| Proximal | 584 (52.0) | 505 (55.9) | 79 (36.1) | <.0001 |
| Distal | 539 (48.0) | 399 (44.1) | 140 (63.9) | |
| Primary site trinary, No. (%) | ||||
| Esophageal | 286 (25.5) | 252 (27.9) | 34 (15.6) | .0001 |
| Gastric | 539 (48.0) | 399 (44.1) | 140 (63.9) | <.0001 |
| Gastroesophageal junction (Siewert I-II) | 298 (26.5) | 253 (28.0) | 45 (20.5) | .03 |
| ERBB2 (formerly HER2 or HER2/neu) status, No. (%) | ||||
| Positive | 226 (20.1) | 195 (21.6) | 31 (14.2) | .02 |
| Negative | 722(64.3) | 570 (63.1) | 152 (69.4) | |
| Unknown | 175 (15.6) | 139 (16.9) | 36 (16.4) | |
| Primary resected, No. (%) | ||||
| Yes | 502 (44.7) | 406 (44.9) | 96 (43.8) | .82 |
| No | 619 (55.1) | 497 (55.0) | 122 (55.7) | |
| Unknown | 2 (0.2) | 1 (0.1) | 1 (0.5) | |
| Stage at diagnosis, No. (%) | ||||
| I | 102 (9.1) | 84 (9.3) | 18 (8.2) | .70 |
| II | 126 (11.2) | 103 (11.4) | 23 (10.5) | .81 |
| III | 289 (25.7) | 237 (26.2) | 52 (23.9) | .49 |
| IV | 603 (53.7) | 478 (52.9) | 125 (57.3) | .26 |
| Unknown | 3 (0.3) | 2 (0.2) | 1 (0) | |
| Metastatic or nonmetastatic at diagnosis, No. (%) | ||||
| Metastatic | 603 (53.7) | 478 (52.9) | 125 (57.1) | .26 |
| Nonmetastatic | 519 (46.2) | 426 (47.1) | 93 (42.5) | |
| Unknown | 1 (0.9) | 0 (0.0) | 1(0.4) |